The exercise, which began on Tuesday, is centred around five high-risk districts of Uganda that border the DRC (Bundibugyo, Kabarole, Kasese, Ntoroko and Bunyangabu) and involves the administering of 2,100 doses of vaccine to health workers, protecting them against the particular strain of Ebola now circulating in some parts of DRC.
It is the first time the vaccine has been offered before an Ebola outbreak even starts.
Ugandan officials say twice-weekly market days _ during which 10,000 Congolese cross into Uganda _ have put the country at high risk.
"Compassionate use of the Ebola vaccine for health care and frontline workers", will begin on Monday, she told journalists.More news: Here are the candidates who made history in the 2018 midterms
Uganda is to administer an experimental Ebola vaccine for health workers in high-risk areas bordering the Democratic Republic of the Congo. Indeed, this particular vaccine is now being administered in DRC and is demonstrating positive protective results and potency against the Ebola virus-Zaire type.
While the vaccine is not available for public use and is considered experimental, it's being handed out under a compassionate use program, the World Health Organization said.
This Merck vaccine candidate rVSV-Ebola was also used in the Ebola outbreak in Equateur province in May-July 2018.
Uganda shares a border with Congo, and both nations experience a robust movement of people between them as a result of trade and the region's high population. There are four experimental treatments being tried out in DRC: ZMapp, a cocktail of antibodies that fight the virus; a second cocktail of antibodies called REGN-EB3; a single-antibody drug called mAb114; and an antiviral drug called remdesivir.Supportive care, including replacing fluids and electrolytes lost to diarrhea and vomiting, can also help keep patients alive.This is the second outbreak of Ebola in Congo this year.More news: Loved ones trying to reach those missing since Thousand Oaks shooting
The targeted districts are Kabarole, Bunyangabo, Kasese, Bundibugyo and Ntoroko, where there is an outbreak of the highly contagious disease.
Recently, the World Health Organization (WHO) said there is not enough valid research to risk the health of pregnant women nor their future child with the investigational vaccine rVSV-ZEBOV.
This preventive exercise has begun in the Ntoroko district which is located in central Africa.
He assured of its potency and ability to protect them effectively.More news: Second Summit with North Korea's Kim in Early 2019